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eTag, You’re It!
Researchers use microarrays to cull from the
30,000 genes identified by the Human
Genome Project those that interact with
environmental toxicants. Generally, any-
where from 50 to 200 genes stand out and
are further scrutinized by time-consuming
bioinformatics algorithms. Now a new tool
called the eTag Assay System rapidly identi-
fies not only genes but also related proteins
without the need for complex sample prepa-
ration and follow-up bioinformatics. eTags
further allow scientists to look at multiple
concentrations of an environmental toxicant
to determine at what dose it becomes toxic,
says Sharat Singh, inventor of
the eTag chemistry and senior
vice president of technology
and assay development at
Aclara Biosciences in Moun-
tain View, California. 
Short for “electrophoretic
tags,” eTags are small fluo-
rescent molecules linked to
nucleic acids or antibodies
and are designed to bind
one specific messenger
RNA or protein, respec-
tively. After the eTag binds
its target, a special propri-
etary enzyme cleaves the
bound eTag from the target.
The signal generated from the
released eTag, called a
“reporter,” is proportional to
the amount of target messenger
RNA or protein in the sample. 
The eTag reporters are
identified by capillary elec-
trophoresis using a capillary-
based DNA sequencer. The
unique charge-to-mass ratio of
each eTag reporter—that is, its
electrical charge divided by its
molecular weight—makes it
show up as a specific peak on
the capillary electrophoresis
readout. 
Unlike microarrays,
samples used with the
eTag system do not
require expensive prepara-
tion steps, such as amplifi-
cation by polymerase chain
reaction. Nanogram quanti-
ties of cells, tissue, blood, or
bodily fluids are mixed directly
with eTag reagents in standard 96-well labo-
ratory microplates. 
The ability to look at genes and proteins
at the same time yields multiple advantages
for researchers. Running only one assay
means less sample is needed, and time and
equipment costs are lower. This ability also
increases the specificity of the assay by con-
firming that certain genes express certain
proteins. Finally, because some genes are reg-
ulated at the transcriptional level and others
at the translational level, measuring genes
and proteins gives a better understanding of
the regulation of gene expression.
Because of the costs related to running
microarrays, researchers often obtain data
for just one dose of a given compound. Yet,
“it would be enlightening to look at one
hundred compounds at ten concentrations
and ten time points to fully understand
toxic reactions,” says Singh. Such a compre-
hensive experiment would require hundreds
of microarrays (at about $300 apiece) and a
few months to complete. In contrast, eTags
could accomplish the task in days, at a cost
of approximately $200. 
Fifty different eTags corresponding to
50 reactions can be combined in one well.
Aclara offers eTag assay kits to detect cer-
tain pathways, such as cytokines and
cytochrome P450s associated with toxicity,
or they can customize sets of eTags to suit a
researcher’s needs. 
At  Stanford University School of
Medicine, rheumatologist Paul J. Utz
received funding from the National Heart,
Lung, and Blood Institute to
use eTags to identify cytokines
and chemokines as biomarkers
for systemic lupus erythemato-
sus and rheumatoid arthritis.
In mouse models of rheuma-
toid arthritis, environmental
toxicants such as mercury trig-
ger the production of charac-
teristic autoantibodies, which
may also be pathogenic. In
past experiments, Utz has
relied on homemade protein
arrays to detect biomarkers
such as autoantibodies and
cytokines. However, these pro-
tein arrays “are a pain to print,
they do not allow us to study
all proteins, and the sensi-
tivity is not as good as
what we get with eTags,”
he says. Moreover, Utz
adds, eTags “are easier to
use and have great flexi-
bility.” 
Because eTags are
small molecules that do
not interfere with biological
processes, the opportunities
for their use are broad, says
Singh, ranging from detecting
biowarfare agents such as
anthrax and smallpox, to dis-
covering biomarkers of cancer.
Aclara scientists have created
600 eTags for genes and pro-
teins relevant to toxicology and
human illnesses, providing sig-
nificant coverage of key targets.
The ultimate goal is to create
1,000 eTags by the end of
2004, says Singh. –Carol Potera
Environews Forum
Man is only man at the surface. Remove the skin, dissect, 
and immediately you come to machinery.
Paul Valéry (1871–1945)
PROTEOMICS
A DNA sequencer identifies
the eTag reporters by capillary
electrophoresis. The unique
charge-to-mass ratio of each
eTag reporter makes it show
up as a specific peak on the
capillary electrophoresis 
readout.
Nanogram quantities of cells, tis-
sue, blood, or body fluids can
be mixed directly with eTag
reagents in standard 96-well
laboratory microplates. Fifty
different eTags (small fluores-
cent molecules linked to
nucleic acids or antibodies)
corresponding to 50 reactions
can be combined in one well.
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The eTag Assay System
eTags bind one specific
messenger RNA or protein. Then
a special proprietary enzyme
cleaves the bound eTags from
the target. The “reporter” sig-
nal generated from the
released eTag is proportional to
the amount of target messenger
RNA or protein in the sample.Forum
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Silencing of Mutant
Genes with RNAi
RNA works hard at the business of
expressing genetic information. It carries
instructions from DNA in the cell nucle-
us into the cytoplasm, where basic house-
keeping functions are carried out and
proteins manufactured. When messenger
RNA arrives in the cytoplasm, it binds to
the ribosomes and guides the assembly of
amino acids into proteins. Now advances
in genomics have led to the discovery
that, in addition to its transport and
manufacturing roles, RNA can silence
gene expression by a process called RNA
interference (RNAi). RNAi provides a
new tool for investigating gene function
that also has potential for developing
novel clinical treatments for certain pre-
viously untreatable diseases.
RNAi is an evolutionarily conserved
cellular mechanism in worms, plants, and
animals. In the RNAi pathway, long
pieces of double-stranded RNA are cut
into smaller pieces by the “dicer” enzyme
to form small interfering RNAs (siRNAs)
that are about 21 nucleotides long. These
siRNAs bind with other molecules to
form the RNA-induced silencing com-
plex, which allows the siRNAs to target
specific messenger RNAs to block pro-
duction of protein. 
In  the 10 June 2003 issue of Proc-
eedings of the National Academy of
Sciences, graduate research assistant
Victor M. Miller, associate neurology
professor Henry L. Paulson, and col-
leagues at the University of Iowa report
results that will faciliate development of
siRNA therapies for heritable diseases
such as Machado-Joseph disease (MJD)
and other dementias in which defective
proteins clump together and impair brain
and nervous system function. In MJD, for
example, a mutation of the MJD1 gene
produces multiple copies of the amino
acid glutamine, which makes a protein
that is toxic to cells. And in frontotempo-
ral dementia with parkinsonism, a muta-
tion of the tau gene produces defective tau
protein consisting of the tangled filaments
that lead to cell death in dementia disor-
ders such as Alzheimer disease. 
Miller and colleagues conducted
experiments using siRNAs to silence
genes of these two diseases. In the exper-
iments, siRNAs were produced in a test
tube, then added to cells to see if they
inhibited or suppressed expression of the
targeted gene. Sequences for siRNAs that
worked were inserted into a plasmid for
production of short hairpin RNA, which
the cell converts into siRNA, using the
specific sequence for each different
siRNA the team wanted to clone. 
Targeting a single-nucleotide differ-
ence between the mutant and healthy
MJD1 gene enabled the scientists to
almost completely eliminate production
of the defective protein in a human cell
model system. The experiments using
siRNAs to knock down expression of the
tau gene also succeeded in reducing pro-
duction of the protein that causes disease. 
Paulson says, “Because the human
genome is full of polymorphisms, includ-
ing countless single-nucleotide polymor-
phisms, it is conceivable that some of
these might be associated with diseases, or
traits, that allow them to be the ‘hook’ by
which selective targeting [of a gene] can
occur.” The ability of siRNAs to knock
down disease-causing proteins coded by
dominant genes offers hope for new and
effective treatment of diseases that other
genetic engineering strategies—such as
gene replacement therapy—cannot
address.
According to Hui Zhang, an associate
professor of genetics at the Yale University
School of Medicine, the paper is highly
significant in that it provides a conceptu-
al as well as potential way of treating
diseases that contain point mutations
through interfering with normal cellular
function. “The authors provided detailed
analysis for allele-specific silencing of the
disease genes using the siRNA approach,
which may provide a therapeutic answer
to many mutation-based diseases,” says
Zhang. “Their conclusion . . . is consis-
tent with our understanding of the siRNA
targeting mechanism reported by many
others.”
The next big hurdle will be to test
siRNAs in an animal model. In a collabo-
ration between Paulson and Beverly
Davidson, the Roy J. Carver Associate
Professor of Internal Medicine at the
University of Iowa, the team is now
employing a viral vector to introduce
siRNAs into mouse models of human
neurodegenerative disease.
Although human therapy is the ulti-
mate goal, there are a number of chal-
lenges ahead before this new technology
will be available. These include possible
rapid degradation of siRNA in the cell,
nonspecific effects on gene expression,
and the need for high specificity to pre-
vent unwanted side effects of treatment,
such as possible interference with other
proteins or biological pathways, or elici-
tation of immune system responses.
–Mary W. Eubanks
INNOVATIVE TECHNOLOGIES
Cross-species application. Because RNA interference is evolutionarily conserved, it may be useful for silencing genes in various animal models of disease.A 810 VOLUME 111 | NUMBER 15 | November 2003 • Environmental Health Perspectives
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ADDLs: A New
Explanation for
Alzheimer
Disease?
Clumps of large, sticky proteins forming
senile plaques have been observed in the
brains of people with Alzheimer disease ever
since neurologist Alois Alzheimer first
described the disorder nearly a century ago.
However,  only in the last few years have
researchers begun to understand how the
primary component of these proteins, a
compound known as β-amyloid (Aβ), dis-
ables and kills brain cells. Recent work
shows that other forms of Aβ known as Aβ-
derived diffusible ligands, or ADDLs, may,
along with senile plaques, play a key role in
the pathogenicity of Alzheimer disease. True
to the promise of environmental medicine,
these findings could contribute to better
methods for diagnosing Alzheimer disease,
as well as new therapies to halt its progress.
Recent research by postdoctoral fellow
Yuesong Gong, neurobiology and physiolo-
gy professor William Klein, and other
researchers at Northwestern University,
published in the 2 September 2003 Proc-
eedings of the National Academy of Sciences,
shows that ADDLs bind to synapses, con-
nection points that allow the exchange of
signals between neurons. There they disrupt
the signaling needed to form memories, says
Klein, a member of the
Northwestern Cognitive
Neurology and Alzheimer’s
Disease Center. 
Aβ is formed by the
breakdown of the amyloid
precursor protein, a mole-
cule of unknown function
that is embedded in the
membrane of some cells. It
is not unusual for cells to
make Aβ, but in persons
with Alzheimer disease, for reasons that are
not yet known, production of Aβ either
dramatically increases or its breakdown
decreases. The Northwestern team found
up to 70 times as many ADDLs in brain tis-
sue from persons with Alzheimer disease
compared to brain tissue from persons
without the disease.
Once formed, Aβ molecules can fold on
themselves and bind to each other. Early in
this process, they link in globules of 12–24
molecules to form ADDLs. Eventually, in a
process described in the 18 April 2003 issue
of Science by a team including Carl Cotman,
director of the University of California,
Irvine, Institute for Brain Aging and
Dementia, ADDLs can bind to cells until
they begin to appear as diffuse plaques. 
In the early 1990s, researchers thought
that plaques were the most toxic form of
Aβ. But recent research indicates that
ADDLs may be more damaging. Studies in
mice have shown that memory loss corre-
lates more strongly with the presence of
ADDLs than with the presence of senile
plaques, and that treatments to reduce
ADDL levels can actually reverse memory
loss. “It’s very likely that [senile plaques] can
be bioactive; they’ve been seen attached to
the sides of nerve cells, but the damage they
cause is probably limited,” says Klein, who
further speculates, “The ADDLs are much
more insidious because they diffuse between
cells until they find just the right target.” 
Cotman’s team and others have also
found that ADDLs are similar in size and
shape to prions, molecules that have been
linked to the transmission of bovine spongi-
form encephalopathy (“mad cow disease”)
and other neurodegenerative diseases. They
may therefore share a common mechanism
of toxicity.
ADDLs have been measured in cere-
brospinal fluid. Measurement of ADDL
levels could eventually serve as a diagnosis
of Alzheimer disease, especially in its early
stages, and could be more accurate than the
cognitive evaluations currently used, says
Klein. His team is working to see if ADDL
levels that correlate to the disease can be
detected in less-invasive blood tests. 
Recent ADDL discoveries could also
contribute to research into potential anti-
amyloid therapies, which currently fall into
three groups: immunotherapies that
prompt the body’s immune system to
destroy Aβ, antiaggregants that keep the
molecules from clumping, and enzyme (sec-
retase) modulators that prevent the creation
of Aβ or hasten its destruction. “All three
approaches show some efficacy in trans-
genic animal models,” says Samuel Gandy,
vice chair of the medical and sci-
entific advisory council of the
Alzheimer’s Association and
director of the Farber Institute
for Neurosciences at Thomas
Jefferson University.
An immunotherapy ap-
proach using vaccine has shown
mixed results so far. Although
some patients in phase II trials
showed cognitive benefits, some
5% also developed acute allergic
encephalitis for reasons yet
unknown. Klein speculates that a
vaccine that focused on Aβ in
ADDL form, as opposed to
plaques, could be more effective,
cause less inflammation, and
require less vaccine. Further, he
says, there are no reasons a priori
that should prevent development
of ADDL-specific therapeutic
antibodies, which would consti-
tute a “passive” vaccine. “It’s a
challenging and exciting
approach, but there’s a lot of
work to go yet,” says Cotman. 
Several drugs to inhibit Aβ
clumping are in clinical trials,
according to Gandy. Enzyme-
based therapies could use exist-
ing compounds—recent studies
indicate that some antioxidants,
including vitamin E and curcumin (the
main ingredient in curry), may inhibit Aβ
accumulation. Other research has shown
that statins (cholesterol-lowering drugs) and
estrogen activate a form of secretase that
destroys Aβ, says Gandy. There are indica-
tions that other lifestyle and environmental
factors may also decrease Aβ levels. For
example, some epidemiology studies link
exercise with delayed onset of Alzheimer
disease, says Cotman. “Ultimately,” he says,
“we may be looking at a combination of
behavior, new drugs, and nutrients to treat
Alzheimer’s disease.” –Kris Freeman
Addled synapses? In a newly discovered
Alzheimer disease process, ligands known
as ADDLs bind to synapses and disrupt the
formation of memories. 
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Harvard Institute of Proteomics txgnet
The discovery, study, and characterization of the
vast number of proteins in the human body is an
enormous challenge. One research center that has
been formed to take on this challenge is the
Harvard Institute of Proteomics (HIP). The HIP’s
website, located at http://www.hip.harvard.edu/,
outlines the institute’s research program.
Founded within the Harvard Medical School in
1999, the HIP is at present laying the groundwork
for determining the function of every protein
encoded by the human genome in order to help
understand how protein malformations con-
tribute to disease. 
Toward this goal, HIP scientists are develop-
ing a novel robotics-based resource known as the
FLEXGene repository, which will contain and dis-
tribute cloned copies of 20,000 human genes.
Once this repository is complete, its developers
say it will allow researchers to look at protein
expression in all experimental formats and at any
chosen scale. Whereas traditional DNA subcloning
is time-consuming and labor-intensive, using
clones from FLEXGene is quick, inexpensive, and
efficient.
The research section of the site contains con-
tact information for and descriptions of the eight
areas of ongoing HIP research. One of these, the
Breast Cancer 1,000 Project, is focused on discov-
ering and understanding the biological functions
of proteins related to breast development and
breast cancer. Eventually, this research group will
develop a repository of clones for 1,000 full-
length complementary DNAs for genes that may
contribute to the onset of breast cancer. The
group is also working to convert their findings
into technologies to support a broad range of
functional experiments. The products generated
through these efforts should also prove useful to
research on other cancers that have been linked
to this group of genes. 
HIP projects devoted to the sequencing of the
genomes of human pathogen organisms and the
building of an expression-ready gene repository
for these gene sets are described on the
Pseudomonas page of the Research section of the
HIP site. Currently HIP investigators are focusing
on developing gene sets for Pseudomonas aerug-
inosa PAO1 (the leading cause of death in cystic
fibrosis patients), the malaria parasite Plas-
modium falciparum 3D7, and strains of arbovirus-
es including West Nile virus and dengue virus
strains 2 and 3. 
Institute researchers are also pushing forward
to clone the entire range of kinases encoded with-
in the human genome and to transfer them to a
database that supports cell-based assays relevant
to processes including growth factor/cytokine
signaling, apoptosis, and immunosuppression.
Information on this project is available in the
Research section, as are snapshots of projects to
develop high-throughput methods for protein
expression and purification, and to devise a
method for producing protein microarrays that is
more streamlined than current processes and
that reduces the need for direct manipulation of
the proteins. 
The Informatics section of the HIP site con-
tains links to databases and web-based programs
used for proteomics applications. For example,
the MedGene database mines text citations from
PubMed to create a “co-occurrence network”
that normalizes and ranks reported human
gene–disease relationships. MedGene can gener-
ate input for disease-specific microarrays, sort
gene profiling data, and compile lists of genes for
use in screening experiments. The programs avail-
able on this page include PCR Oligo Calculator,
which lets researchers design batch polymerase
chain reaction primers for amplifying the open
reading frames for a given set of genes, and Batch
Gene Retriever, which allows downloads of full-
length sequence information from National
Center for Biotechnology Information databases
in batch mode. –Erin E. DooleyA 812 VOLUME 111 | NUMBER 15 | November 2003 • Environmental Health Perspectives
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Crunching the 
Bio-numbers
The quest is on to extract useful informa-
tion from the growing mountain of data
from today’s high-throughput, high-tech
biology, and there is a constant demand for
new data-mining techniques that are faster
and smarter. The work presented at a recent
symposium session on microarray and gene
expression analysis shows how bio-number
crunchers are contributing many ingenious
new approaches to finding the scientific
needles in the raw data haystacks.
The session was part of the Atlantic
Symposium on Computational Biology
and Genome Informatics, which was one
of 11 conferences, symposia, and work-
shops convened under the umbrella of the
7th Joint Conference on Information
Sciences, held 26–30 September 2003 in
Research Triangle Park, North Carolina.
The conference was sponsored by the
NIEHS, the Association for Intelligent
Machinery, Duke University, the journal
Information Sciences, and the Harbin
Institute of Technology in China. 
According to session chair Björn
Olsson, a lecturer in computer sciences at
the University of Skövde, Sweden, the pre-
sentations showed that the field of bioin-
formatics is coming to terms with the
capabilities it has to offer. “Going back a
few years, when this type of data was com-
pletely new and everyone was excited
about it, I think people were fumbling in
the dark a bit about what to do with all of
this data,” he says. “It’s becoming more
clear now what directions we can go in.”
Simon Lin, manager of the Duke
Bioinformatics Shared Resource, led off
the session by presenting the results of a
study he and colleagues recently complet-
ed proposing an improved method of data
classification in proteomics-based research
using matrix-assisted laser desorption/ion-
ization time-of-flight (MALDI-TOF)
mass spectrometry, an enhanced version of
the original technology used for protein
identification. Peaks from MALDI-TOF
raw data (which exhibit the proteins extant
in a biosample) must be brought into reg-
istration to correct for random fluctuations
before they can be used to classify samples
(for example, as diseased or nondiseased).
Lin and his team used a new algorithmic
approach to the registration problem,
employing a statistical model based on the
chemical analysis of normal mixtures to
achieve registration. 
Applying this method to an existing
data set of 11 tissue samples from cancer-
ous lungs and 11 samples from healthy
lungs achieved a classification rate of
90.9%, with a false-positive rate of 0%.
Further, the researchers correctly identified
two previously known lung cancer protein
markers in the cancerous samples, and dis-
covered seven novel markers worthy of fur-
ther investigation for biologic relevance.
Improving the accurate classification
of diseased versus nondiseased samples is
one of the ongoing challenges in the world
of bioinformatics. “Decision trees” help
researchers classify samples by offering
sequential tests of individual attributes.
The result of each test determines which
test, or branch, should be applied next,
until a final classification is reached.
Olsson presented work in which he and
his colleagues applied the decision tree
algorithm C4.5 to microarray-based gene
expression data in order to induce deci-
sion trees for identification of breast can-
cer patients. 
Using the expression values of the 108
genes identified in the literature as breast
More than a mouthful. A recent bioinformatics meeting highlighted the many data-crunching technologies being brought to bear on the “-omics.”
BIOINFORMATICScancer–related as input to the decision
tree algorithm, the team analyzed gene
expression data from 75 women, 53 of
whom had been diagnosed with breast
cancer. The decision tree method
achieved 89% accuracy in classifying sam-
ples, based on their gene expression data.
Olsson also described the potential utility
of decision tree algorithms to study sig-
naling pathways based on gene expression
data, as well as to discover additional can-
cer-related genes.
From decision trees, graduate student
Tao Shi of the Department of Human
Genetics at the University of California,
Los Angeles, took the audience into the
woods as he described the use of “random
forest” predictors to derive information
from microarray data. The random forest
approach, which uses a suite of decision
trees, can be used to detect clusters in the
data, a vital and informative but often dif-
ficult step in accurate classification. Shi
showed that the random forest approach
could help meet the challenge of using
gene expression data to classify tumor
types, which is increasingly important in
molecular biology efforts to characterize
cancer subtypes.
Rounding out the session, mathemati-
cian Takeharu Yamanaka and research fel-
low Fred Parham of the NIEHS Laboratory
of Computational Biology and Risk
Analysis presented a new method of ana-
lyzing gene expression to infer genetic
interactions, which can help identify sig-
nal transduction pathways crucial to the
sequence of biochemical events that con-
trol cellular function. The method uses a
Bayesian network, a type of mathematical
framework useful for representing known
or hypothesized causal relationships. The
network measures levels of messenger
RNA from different genes and uses condi-
tional assumptions to represent the influ-
ence one gene has on another. “By using
the Bayesian network,” says Yamanaka,
“we can incorporate statistical thought
into the analysis, unlike present methods.”
Parham adds, “Also, with the Bayesian
networks, we can hopefully . . . say not
just that this group of genes is related, but
we can also see the causality.”
As today’s automated, high-through-
put instruments routinely churn out
masses of data that would have been
unimaginable just a decade ago, innova-
tions in bioinformatics such as those pre-
sented at the session will be required to
bring method to the madness, and ulti-
mately help deliver the improvements in
human and environmental health prom-
ised by molecular biology. –Ernie Hood
Forum
Environmental Health Perspectives • VOLUME 111 | NUMBER 15 | November 2003 A 813